This case study presentation will delve into the executive order that President Biden issued on March 18th, 2024 and how it impacts the biotech community with early-stage drug research and development. We will discuss what this means, how to move forward, and what might change as a result of this long overdue order and focus. Explore how this order will facilitate easier access to resources and funding, making women's health initiatives more accessible and impactful. Gain insights into the evolving strategies of researchers and scientists in response to this new focus, and discuss the long-term implications for drug development, research, and funding in women's health.
